FINACEA

Finacea Adverse Events Reported to the FDA Over Time

How are Finacea adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Finacea, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Finacea is flagged as the suspect drug causing the adverse event.

Most Common Finacea Adverse Events Reported to the FDA

What are the most common Finacea adverse events reported to the FDA?

Burning Sensation	59 (6.71%)
Erythema	57 (6.48%)
Rosacea	55 (6.26%)
Pruritus	35 (3.98%)
Rash	25 (2.84%)
Skin Irritation	23 (2.62%)
Skin Burning Sensation	22 (2.5%)
Skin Disorder	22 (2.5%)
Acne	21 (2.39%)
Dry Skin	19 (2.16%)
Paraesthesia	17 (1.93%)
	Show More
Vision Blurred	14 (1.59%)
Application Site Paraesthesia	13 (1.48%)
Alopecia	12 (1.37%)
Angina Pectoris	12 (1.37%)
Application Site Irritation	12 (1.37%)
Mass	12 (1.37%)
Mood Altered	12 (1.37%)
Nervousness	12 (1.37%)
Onychomycosis	12 (1.37%)
Pain In Extremity	12 (1.37%)
Weight Increased	12 (1.37%)
Hypersensitivity	11 (1.25%)
Pain	11 (1.25%)
Skin Exfoliation	11 (1.25%)
Drug Ineffective	10 (1.14%)
Facial Pain	10 (1.14%)
Oral Herpes	10 (1.14%)
Abdominal Pain	9 (1.02%)
Application Site Pain	9 (1.02%)
Fatigue	9 (1.02%)
Sensation Of Heaviness	9 (1.02%)
Skin Discolouration	9 (1.02%)
No Adverse Event	8 (.91%)
Adverse Event	7 (.8%)
Pain Of Skin	6 (.68%)
Swelling Face	6 (.68%)
Hypertrichosis	5 (.57%)
Affect Lability	4 (.46%)
Application Site Dryness	4 (.46%)
Application Site Erythema	4 (.46%)
Application Site Rash	4 (.46%)
Dermatitis Contact	4 (.46%)
Feeling Hot	4 (.46%)
Rash Macular	4 (.46%)
Urticaria	4 (.46%)
Abnormal Sensation In Eye	3 (.34%)
Application Site Burn	3 (.34%)
Blister	3 (.34%)
Blood Pressure Systolic Increased	3 (.34%)
Chemical Burn Of Skin	3 (.34%)
Dermatitis	3 (.34%)
Dizziness	3 (.34%)
Dyspnoea	3 (.34%)
Eye Irritation	3 (.34%)
Eye Pain	3 (.34%)
Eye Swelling	3 (.34%)
Nausea	3 (.34%)
Nephrolithiasis	3 (.34%)
Ocular Hyperaemia	3 (.34%)
Rash Erythematous	3 (.34%)
Renal Failure Acute	3 (.34%)
Renal Tubular Necrosis	3 (.34%)
Skin Warm	3 (.34%)
Suffocation Feeling	3 (.34%)
Tremor	3 (.34%)
Appendicectomy	2 (.23%)
Application Site Discharge	2 (.23%)
Application Site Pruritus	2 (.23%)
Asthenia	2 (.23%)
Asthma	2 (.23%)
Cellulitis	2 (.23%)
Chest Discomfort	2 (.23%)
Diabetic Neuropathy	2 (.23%)
Drug Use For Unknown Indication	2 (.23%)
Dysgeusia	2 (.23%)
Flushing	2 (.23%)
Haemorrhage	2 (.23%)
Headache	2 (.23%)
Inflammation	2 (.23%)
Malignant Melanoma	2 (.23%)
Medication Residue	2 (.23%)
Non-cardiac Chest Pain	2 (.23%)
Oedema Peripheral	2 (.23%)
Photosensitivity Reaction	2 (.23%)
Rash Papular	2 (.23%)
Rash Pustular	2 (.23%)
Retinal Vein Occlusion	2 (.23%)
Scar	2 (.23%)
Seborrhoea	2 (.23%)
Skin Cancer	2 (.23%)
Skin Reaction	2 (.23%)
Sunburn	2 (.23%)
Thermal Burn	2 (.23%)
Toe Amputation	2 (.23%)
Treatment Noncompliance	2 (.23%)
Visual Impairment	2 (.23%)
Vomiting	2 (.23%)
Wheezing	2 (.23%)
Abortion Induced	1 (.11%)
Abortion Spontaneous	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Finacea, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Finacea is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Finacea

What are the most common Finacea adverse events reported to the FDA?

Epidermal And Dermal Conditions	269 (30.6%)
Skin Appendage Conditions	99 (11.26%)
Neurological	83 (9.44%)
Administration Site Reactions	57 (6.48%)
Musculoskeletal And Connective Tiss...	24 (2.73%)
Therapeutic And Nontherapeutic Effe...	19 (2.16%)
Vision	17 (1.93%)
Mood Disorders	16 (1.82%)
Gastrointestinal Signs	15 (1.71%)
Coronary Artery	14 (1.59%)
Anxiety Disorders	13 (1.48%)
	Show More
Tissue	13 (1.48%)
Allergic Conditions	12 (1.37%)
Fungal Infectious	12 (1.37%)
Physical Examination Topics	12 (1.37%)
Viral Infectious	11 (1.25%)
Respiratory	8 (.91%)
Eye	7 (.8%)
Ocular Infections, Irritations And ...	6 (.68%)
Renal Disorders	6 (.68%)
Cardiac And Vascular Investigations	5 (.57%)
Chemical Injury And Poisoning	5 (.57%)
Angiedema And Urticaria	4 (.46%)
Bronchial Disorders	4 (.46%)
Headaches	4 (.46%)
Infections - Pathogen Unspecified	4 (.46%)
Injuries By Physical Agents	4 (.46%)
Movement Disorders	4 (.46%)
Oral Soft Tissue Conditions	4 (.46%)
Skin Neoplasms Malignant And Unspec...	4 (.46%)
Injuries	3 (.34%)
Ocular Sensory Symptoms	3 (.34%)
Peripheral Neuropathies	3 (.34%)
Product Quality Issues	3 (.34%)
Urolithiases	3 (.34%)
Vascular	3 (.34%)
Bacterial Infectious	2 (.23%)
Bone And Joint Therapeutic Procedur...	2 (.23%)
Cornification And Dystrophic Skin	2 (.23%)
Gastrointestinal Therapeutic Proced...	2 (.23%)
Lifestyle Issues	2 (.23%)
Medication Errors	2 (.23%)
Pigmentation	2 (.23%)
Retina, Choroid And Vitreous Hemorr...	2 (.23%)
Therapeutic Procedures And Supporti...	2 (.23%)
Vascular Hemorrhagic	2 (.23%)
Abortions And Stillbirth	1 (.11%)
Anemias Nonhemolytic And Marrow Dep...	1 (.11%)
Bladder And Bladder Neck Disorders	1 (.11%)
Cardiac Arrhythmias	1 (.11%)
Central Nervous System Vascular	1 (.11%)
Chromosomal Abnormalities And Abnor...	1 (.11%)
Deliria	1 (.11%)
Electrolyte And Fluid Balance Condi...	1 (.11%)
Gastrointestinal Motility And Defec...	1 (.11%)
Gastrointestinal Ulceration And Per...	1 (.11%)
Hematological And Lymphoid Tissue T...	1 (.11%)
Malabsorption Conditions	1 (.11%)
Miscellaneous And Site Unspecified ...	1 (.11%)
Musculoskeletal And Connective Tiss...	1 (.11%)
Myocardial	1 (.11%)
Nervous System Neoplasms Malignant ...	1 (.11%)
Neurological, Special Senses And Ps...	1 (.11%)
Obstetric And Gynecological Therape...	1 (.11%)
Personality Disorders	1 (.11%)
Pregnancy, Labour, Delivery And Pos...	1 (.11%)
Salivary Gland Conditions	1 (.11%)
Skin And Subcutaneous Tissue	1 (.11%)
Sleep Disorders	1 (.11%)
Suicidal And Self-injurious Behavio...	1 (.11%)
Tongue Conditions	1 (.11%)
Upper Respiratory Tract Disorders	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Finacea, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Finacea is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.